Structural Reorganisation and Potential Toxicity of Oligomeric Species Formed during the Assembly of Amyloid Fibrils
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Increasing evidence indicates that oligomeric protein assemblies may represent the molecular species responsible for cytotoxicity in a range of neurological disorders including Alzheimer and Parkinson diseases. We use all-atom computer simulations to reveal that the process of oligomerization can be divided into two steps. The first is characterised by a hydrophobic coalescence resulting in the formation of molten oligomers in which hydrophobic residues are sequestered away from the solvent. In the second step, the oligomers undergo a process of reorganisation driven by interchain hydrogen bonding interactions that induce the formation of beta sheet rich assemblies in which hydrophobic groups can become exposed. Our results show that the process of aggregation into either ordered or amorphous species is largely determined by a competition between the hydrophobicity of the amino acid sequence and the tendency of polypeptide chains to form arrays of hydrogen bonds. We discuss how the increase in solvent-exposed hydrophobic surface resulting from such a competition offers an explanation for recent observations concerning the cytotoxicity of oligomeric species formed prior to mature amyloid fibrils.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,423 · cited 3×
“In other words, the degree of order of a b sheet increases with its size, a finding that is consistent with the extremely high degree of long-range order found in amyloid fibrils [6,35].”
BackgroundMethodInfluentialSelf-citationProtein folding and misfolding
Dobson, C. M. (2003) · Nature · doi:10.1038/nature02261 · Cited by 4,791
Self-citationSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“In this paper we investigate the early stages of the oligomerization process for two fragments (Ab16–22 and Ab25–35) of theAbpeptide, a key pathogenic agent inAlzheimer disease [21] by using all-atom computer simulations (see Methods) able to describe the essence of peptide aggregation reactions at the molecular level…”
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“]. Although the identification of the species giving rise to neurodegeneration is one of the most controversial topics in current studies of misfolding diseases, evidence is accumulating concerning the ability of the low molecular weight oligomers of the Aβ peptide specifically to disrupt cognitive function [”
BackgroundCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434 · cited 3×
“This latter observation has been demonstrated for both diseaseand nondisease-related peptides and proteins [22,24,26].”
BackgroundResultSelf-citationProtein misfolding, evolution and disease
Dobson, C. M. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01445-0 · Cited by 1,952 · cited 1×
“], which include Alzheimer and Parkinson diseases, type II diabetes, and the spongiform encephalopathies, that are rapidly becoming a major challenge in terms of their social and economic impact on society. In addition, there is increasing evidence that the formation of ordered aggregates, known as amyloid fibrils, is…”
BackgroundSelf-citationNatural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2005) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,687
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Folding proteins in fatal ways
Selkoe, D. J. (2003) · Nature · doi:10.1038/nature02264 · Cited by 1,417 · cited 1×
“The phenomenon of protein aggregation is associated with a variety of human disorders [”
Background
Cited by
The amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
Self-citationThe proteostasis network and its decline in ageing
Hipp, M. S., Kasturi, P., & Hartl, F. U. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0101-y · Cited by 1,642
Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein
Cremades, N., Cohen, S. I. A., Deas, E., Abramov, A. Y., Chen, A. Y., Orte, A., Sandal, M., Clarke, R. W., Dunne, P., Aprile, F. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.037 · Cited by 911
Self-citationThe Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
Amyloid β Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies
Nasica-Labouze, J., Nguyen, P. H., Sterpone, F., Berthoumieu, O., Buchete, N.-V., Coté, S., De Simone, A., Doig, A. J., Faller, P., Garcia, A., et al. (2015) · Chemical Reviews · doi:10.1021/cr500638n · Cited by 584
A causative link between the structure of aberrant protein oligomers and their toxicity
Campioni, S., Mannini, B., Zampagni, M., Pensalfini, A., Parrini, C., Evangelisti, E., Relini, A., Stefani, M., Dobson, C. M., Cecchi, C., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.283 · Cited by 552
Self-citationLee, W.-H., Loo, C.-Y., Bebawy, M., Luk, F., Mason, R., & Rohanizadeh, R. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040002 · Cited by 537
ATR-FTIR: A “rejuvenated” tool to investigate amyloid proteins
Sarroukh, R., Goormaghtigh, E., Ruysschaert, J.-M., & Raussens, V. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.012 · Cited by 446
Karpinar, D. P., Balija, M. B. G., Kügler, S., Opazo, F., Rezaei‐Ghaleh, N., Wender, N., Kim, H., Taschenberger, G., Falkenburger, B. H., Heise, H., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.257 · Cited by 432
ANS Binding Reveals Common Features of Cytotoxic Amyloid Species
Bolognesi, B., Kumita, J. R., Barros, T. P., Esbjorner, E. K., Luheshi, L. M., Crowther, D. C., Wilson, M. R., Dobson, C. M., Favrin, G., & Yerbury, J. J. (2010) · ACS Chemical Biology · doi:10.1021/cb1001203 · Cited by 389
Self-citationOligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity
Fändrich, M. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.006 · Cited by 340
Protein Folding and Mechanisms of Proteostasis
Díaz-Villanueva, J., Díaz-Molina, R., & García-González, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817193 · Cited by 338
Abby, S. S., & Rocha, E. P. C. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002983 · Cited by 314
Miller, Y., Ma, B., & Nussinov, R. (2010) · Chemical Reviews · doi:10.1021/cr900377t · Cited by 286
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 269
Qiao, Q., Bowman, G. R., & Huang, X. (2013) · Journal of the American Chemical Society · doi:10.1021/ja403147m · Cited by 182
Stefani, M. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.002 · Cited by 177
Cholesterol in Alzheimer’s Disease and other Amyloidogenic Disorders
Harris, J. R., & Milton, N. G. N. (2010) · Subcellular Biochemistry · doi:10.1007/978-90-481-8622-8_2 · Cited by 44
Malishev, R., Nandi, S., Kolusheva, S., Shaham-Niv, S., Gazit, E., & Jelinek, R. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.06.019 · Cited by 21
“2 and 3, likely results in lower abundance of early-fibril intermediates which are membraneactive and believed to constitute the primary toxic species in amyloid systems [42].”
Background
Metadata
- Authors
- Cheon, M., Chang, I., Mohanty, S., Luheshi, L. M., Dobson, C. M., Vendruscolo, M., & Favrin, G.
- Venue
- PLoS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-09-14
- Volume
- 3
- Issue
- 9
- Pages
- e173
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- OpenAlex
- W2037346440
- Cited by
- 215
- References
- 59
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.